Zhang, CongShestopaloff, KonstantinHollis, BenjaminHei Kwok, ChunHon, ClaudiaHartmann, NicoleTian, ChengengWozniak, Magdalena BSantos, LuisWest, Dominique MGardiner, StephenMallon, Ann-MarieReadie, AimeeMartin, RuvieNichols, ThomasBeste, Michael TZierer, JonasFerrero, EnricoVandemeulebroecke, MarcJostins-Dean, Luke2024-07-312024-07-312023-10-05Zhang, C, Shestopaloff, K, Hollis, B, Hei Kwok, C, Hon, C, Hartmann, N, Tian, C, Wozniak, M B, Santos, L, West, D M, Gardiner, S, Mallon, A-M, Readie, A, Martin, R, Nichols, T, Beste, M T, Zierer, J, Ferrero, E, Vandemeulebroecke, M & Jostins-Dean, L 2023, 'Response to anti-IL17 therapy in inflammatory disease is not strongly impacted by genetic background', American Journal of Human Genetics, vol. 110, no. 10, pp. 1817-1824. https://doi.org/10.1016/j.ajhg.2023.08.0100002-9297PubMedCentral: PMC10577077ORCID: /0000-0003-3933-4967/work/164969062https://hdl.handle.net/2164/23948C.Z., C.H., N.H., C.T., M.W., A.R., R.M., M.T.B., J.Z., E.F., and M.V. are employees and stock owners of Novartis AG or its subsidiaries. Other authors, including K.S., C.H.K., L.S., D.W., and S.G. were funded by the BDI-Novartis Collaboration for AI in Medicine, which is funded by a grant from Novartis AG. Novartis AG manufactures and markets secukinumab and has an ongoing commercial interest in its success.83076006engbiological therapyclinical trialsgenome-wide association studiesinflammatory diseasesrheumatic diseasesHumansPsoriasis/drug therapyArthritis, Rheumatoid/drug therapyGenotypeArthritis, Psoriatic/drug therapyR MedicineGenetics(clinical)GeneticsSupplementary InformationRJournal article10.1016/j.ajhg.2023.08.010http://www.scopus.com/inward/record.url?scp=85173495119&partnerID=8YFLogxK11010